Compare Cytokinetics Inc (CYTK) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Expeditors International of Wshngtn Inc — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Expeditors International of Wshngtn Inc trades at $194 (market cap $25.18B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 2.9× Cytokinetics Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.84% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Expeditors International of Wshngtn Inc for 43 Days on average.
| CYTK | EXPD | |
|---|---|---|
Market Cap | $8.62B | $25.18B |
Volume | 2,594,626 | 1,003,557 |
Sector | Health | Industrials |
52-Week High | $87.26 | $194.12 |
52-Week Low | $54.76 | $113.13 |
Typical Hold Time | 19 Days | 43 Days |
Enterprise Value | $8.72B | $24.72B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
EXPD trades at $190.85, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $2.20 EPS. Revenue growth is steady, rising from $10.6B in 2024 to a projected $12.0B in 2026, while net income margins remain stable around 7.6%. Recent news highlights efficiency initiatives and airfreight demand as positive catalysts.
Outlook is mixed: strong profitability and earnings beats support upside, but a high P/E of 28.2 suggests premium valuation risks. Analyst consensus is cautious with 63.6% hold ratings, and the consensus price target of $179.43 implies potential downside. Key risks include freight market volatility and execution challenges amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
